Camilleri Michael, Ford Alexander C
Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.) and Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA.
Leeds Institute of Biomedical and Clinical Sciences, University of Leeds and Leeds Gastroenterology Institute, Leeds Teaching Hospitals Trust, Leeds LS9 7TF, UK.
J Clin Med. 2017 Oct 27;6(11):101. doi: 10.3390/jcm6110101.
Irritable bowel syndrome (IBS) is a disorder of the brain-gut axis; the pathophysiological mechanisms include altered colonic motility, bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier and secretory properties of the gut. This article reviews the mechanisms, efficacy, and safety of current pharmacotherapy, and medications that are in phase III trials for the treatment of IBS. There remains a significant unmet need for effective treatments-particularly for the pain component of IBS-although the introduction of drugs directed at secretion, motility and a non-absorbable antibiotic provide options for the bowel dysfunction in IBS.
肠易激综合征（IBS）是一种脑-肠轴紊乱疾病；其病理生理机制包括结肠动力改变、胆汁酸代谢、神经激素调节、免疫功能障碍、上皮屏障改变以及肠道分泌特性改变。本文综述了当前药物治疗的机制、疗效和安全性，以及处于治疗IBS的III期试验阶段的药物。尽管针对分泌、动力和一种不可吸收抗生素的药物为IBS的肠道功能障碍提供了选择，但对于有效治疗仍有巨大的未满足需求，尤其是针对IBS疼痛症状的治疗。
